Identity
Amycretin is a single-molecule investigational GLP-1 and amylin receptor agonist.
Selected study only; not a complete clinical review.
Peptide library
Amycretin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The cited first-in-human oral study primarily characterizes exposure and tolerability. Weight changes are exploratory, and results cannot be reassigned to a subcutaneous formulation or compared directly with phase III products.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
144 adults with overweight or obesity; first-in-human oral phase 1 trial.
What the sources found
The study characterized oral exposure and tolerability; weight outcomes were exploratory and require later-phase confirmation.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
Amycretin is a single-molecule investigational GLP-1 and amylin receptor agonist.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Events were mild or moderate, commonly gastrointestinal, and increased with dose.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The study characterized oral exposure and tolerability; weight outcomes were exploratory and require later-phase confirmation.
Selected study only; not a complete clinical review.
Adverseeffects
Events were mild or moderate, commonly gastrointestinal, and increased with dose.
Selected study only; not a complete clinical review.
References
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. 2025.
PMID: 40550229
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.